Special population considerations and regulatory affairs for clinical research

Kristin N Grimsrud, Catherine M.T. Sherwin, Jonathan E. Constance, Casey Tak, Athena F. Zuppa, Michael G. Spigarelli, Nicole L. Mihalopoulos

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Special populations, including women (non-pregnant and pregnant), pediatrics, and the elderly, require additional consideration with regard to clinical research. There are very specific regulatory laws, which protect these special populations, that need to be understood and adhered to in order to perform clinical research. This review provides a broad overview of some of the physiological differences in special populations and discusses how these differences may affect study design and regulatory considerations. These various special populations, with respect to regulatory affairs, are clearly defined within the Code of Federal Regulations. The definition of "special population" exists to provide enhanced awareness of their vulnerabilities, thereby allowing the creation of regulatory guidance aimed to decrease injury or outright harm. Currently, progress is being made to be more inclusive of special populations in clinical trials. This reflects changing attitudes towards drug information, with it being more representative of those patients that will ultimately be prescribed or exposed to the therapy. However, all research undertaken in these populations should be performed in a manner that ensures all protections of each participant are upheld.

Original languageEnglish (US)
Pages (from-to)47-56
Number of pages10
JournalClinical Research and Regulatory Affairs
Volume32
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Research
Population
Patient Advocacy
Pregnant Women
Clinical Trials
Pediatrics
Wounds and Injuries
Pharmaceutical Preparations
Therapeutics

Keywords

  • Geriatrics
  • Human subject research
  • Pediatrics
  • Pregnancy
  • Regulations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Grimsrud, K. N., Sherwin, C. M. T., Constance, J. E., Tak, C., Zuppa, A. F., Spigarelli, M. G., & Mihalopoulos, N. L. (2015). Special population considerations and regulatory affairs for clinical research. Clinical Research and Regulatory Affairs, 32(2), 47-56. https://doi.org/10.3109/10601333.2015.1001900

Special population considerations and regulatory affairs for clinical research. / Grimsrud, Kristin N; Sherwin, Catherine M.T.; Constance, Jonathan E.; Tak, Casey; Zuppa, Athena F.; Spigarelli, Michael G.; Mihalopoulos, Nicole L.

In: Clinical Research and Regulatory Affairs, Vol. 32, No. 2, 01.01.2015, p. 47-56.

Research output: Contribution to journalReview article

Grimsrud, KN, Sherwin, CMT, Constance, JE, Tak, C, Zuppa, AF, Spigarelli, MG & Mihalopoulos, NL 2015, 'Special population considerations and regulatory affairs for clinical research', Clinical Research and Regulatory Affairs, vol. 32, no. 2, pp. 47-56. https://doi.org/10.3109/10601333.2015.1001900
Grimsrud, Kristin N ; Sherwin, Catherine M.T. ; Constance, Jonathan E. ; Tak, Casey ; Zuppa, Athena F. ; Spigarelli, Michael G. ; Mihalopoulos, Nicole L. / Special population considerations and regulatory affairs for clinical research. In: Clinical Research and Regulatory Affairs. 2015 ; Vol. 32, No. 2. pp. 47-56.
@article{8ee069b107d14fc8b29b8f34b725822d,
title = "Special population considerations and regulatory affairs for clinical research",
abstract = "Special populations, including women (non-pregnant and pregnant), pediatrics, and the elderly, require additional consideration with regard to clinical research. There are very specific regulatory laws, which protect these special populations, that need to be understood and adhered to in order to perform clinical research. This review provides a broad overview of some of the physiological differences in special populations and discusses how these differences may affect study design and regulatory considerations. These various special populations, with respect to regulatory affairs, are clearly defined within the Code of Federal Regulations. The definition of {"}special population{"} exists to provide enhanced awareness of their vulnerabilities, thereby allowing the creation of regulatory guidance aimed to decrease injury or outright harm. Currently, progress is being made to be more inclusive of special populations in clinical trials. This reflects changing attitudes towards drug information, with it being more representative of those patients that will ultimately be prescribed or exposed to the therapy. However, all research undertaken in these populations should be performed in a manner that ensures all protections of each participant are upheld.",
keywords = "Geriatrics, Human subject research, Pediatrics, Pregnancy, Regulations",
author = "Grimsrud, {Kristin N} and Sherwin, {Catherine M.T.} and Constance, {Jonathan E.} and Casey Tak and Zuppa, {Athena F.} and Spigarelli, {Michael G.} and Mihalopoulos, {Nicole L.}",
year = "2015",
month = "1",
day = "1",
doi = "10.3109/10601333.2015.1001900",
language = "English (US)",
volume = "32",
pages = "47--56",
journal = "Clinical Research Practices and Drug Regulatory Affairs",
issn = "1060-1333",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Special population considerations and regulatory affairs for clinical research

AU - Grimsrud, Kristin N

AU - Sherwin, Catherine M.T.

AU - Constance, Jonathan E.

AU - Tak, Casey

AU - Zuppa, Athena F.

AU - Spigarelli, Michael G.

AU - Mihalopoulos, Nicole L.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Special populations, including women (non-pregnant and pregnant), pediatrics, and the elderly, require additional consideration with regard to clinical research. There are very specific regulatory laws, which protect these special populations, that need to be understood and adhered to in order to perform clinical research. This review provides a broad overview of some of the physiological differences in special populations and discusses how these differences may affect study design and regulatory considerations. These various special populations, with respect to regulatory affairs, are clearly defined within the Code of Federal Regulations. The definition of "special population" exists to provide enhanced awareness of their vulnerabilities, thereby allowing the creation of regulatory guidance aimed to decrease injury or outright harm. Currently, progress is being made to be more inclusive of special populations in clinical trials. This reflects changing attitudes towards drug information, with it being more representative of those patients that will ultimately be prescribed or exposed to the therapy. However, all research undertaken in these populations should be performed in a manner that ensures all protections of each participant are upheld.

AB - Special populations, including women (non-pregnant and pregnant), pediatrics, and the elderly, require additional consideration with regard to clinical research. There are very specific regulatory laws, which protect these special populations, that need to be understood and adhered to in order to perform clinical research. This review provides a broad overview of some of the physiological differences in special populations and discusses how these differences may affect study design and regulatory considerations. These various special populations, with respect to regulatory affairs, are clearly defined within the Code of Federal Regulations. The definition of "special population" exists to provide enhanced awareness of their vulnerabilities, thereby allowing the creation of regulatory guidance aimed to decrease injury or outright harm. Currently, progress is being made to be more inclusive of special populations in clinical trials. This reflects changing attitudes towards drug information, with it being more representative of those patients that will ultimately be prescribed or exposed to the therapy. However, all research undertaken in these populations should be performed in a manner that ensures all protections of each participant are upheld.

KW - Geriatrics

KW - Human subject research

KW - Pediatrics

KW - Pregnancy

KW - Regulations

UR - http://www.scopus.com/inward/record.url?scp=84937842346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937842346&partnerID=8YFLogxK

U2 - 10.3109/10601333.2015.1001900

DO - 10.3109/10601333.2015.1001900

M3 - Review article

AN - SCOPUS:84937842346

VL - 32

SP - 47

EP - 56

JO - Clinical Research Practices and Drug Regulatory Affairs

JF - Clinical Research Practices and Drug Regulatory Affairs

SN - 1060-1333

IS - 2

ER -